May 15,Johnson & Johnson Vision Asia-Pacific President's Email Notification:Several Senior Executives of Eye Power Health Resign Simultaneously.

This situation is very rare, and the following is the original text of the company's email notification:

1/Dear colleagues:

Today, I would like to share with you: after nearly 10 years of serving Johnson & Johnson,Wang Liping, Vice President of Johnson & Johnson Vision in mainland China and Hong Kong, is about to step down.

We will announce the successor to this position at a later date. Despite the management adjustments, we remain firmly committed to becoming the leader in China's eye health market.

2/

What I want to share with you is:Johnson & Johnson Vision China Cataract Business Leader Wang Jiyan to Step DownJi Yan has worked at Johnson & Johnson for 20 years and recently led the cataract product-related business in the Chinese market. We will announce the successor to this position at a later date.

3/

National Sales Director Chen ZhipingThe confirmed last working day is 2024/05/14, and the resignation settlement process has now begun.

Previously, on April 23, Johnson & Johnson announced in an internal email,Song Weiqun, Chairman of Johnson & Johnson China and President of Johnson & Johnson Medical Technology ChinaHave tendered resignation to the company after careful consideration, seeking external development opportunities. As the first China-born chairman of Johnson & Johnson's China region in over a century of the company's history,Song WeiqunThe departure, to some extent, signifies the end of an era for Johnson & Johnson in China.

Personnel upheavals at the top levels of a company often become a "watershed" moment for the direction of its business development.

April 17,Johnson & Johnson's Q1 2024 earnings report shows total revenue of $21.383 billion (approximately RMB 154.789 billion), a year-on-year increase of 2.3%, with a net profit of $5.354 billion, showing steady growth.Still Ranked as a Pharmaceutical Giant in Q1 2024The first.

Among them, the medical technology business revenue was 78.21 billion U.S. dollars, a year-on-year increase of 4.5%. The sales of the subordinate surgical business were 24.16 billion U.S. dollars, a year-on-year increase of 0.7%; the sales of the orthopedics business were 23.40 billion U.S. dollars, a year-on-year increase of 4.3%; the sales of the cardiovascular business were 18.06 billion U.S. dollars, a year-on-year increase of 20.2%; the sales of the vision business were 12.58 billion U.S. dollars, a year-on-year increase of 3.3%.

GE Healthcare Q1 2024 Earnings Report

In the wave of healthcare reform in the Chinese market, leading multinational giants like Johnson & Johnson are actively exploring new models and seeking transformation.

Looking forward to Johnson & Johnson embarking on its next brilliant chapter amidst transformation.